Vitafoods 13/5/2003: Long-term study demonstrates significant effects on body composition
The results of the first long-term study on Tonalin® conjugated linoleic acid (CLA) demonstrate that supplementation with CLA may lead to a significant reduction in body fat and an increase in lean body mass. Study co-ordinator, Dr Jean-Michel Gaullier, presented the latest results of his research “Efficacy and safety of oneyear supplementation with conjugated linoleic acid in moderate overweight” at the 94th AOCS* meeting in Kansas City, USA last week.
“This study is particularly significant because, we are able to demonstrate for the first time, long term effects of CLA in humans and on a large population”, he explained. “In addition, this study was performed under the strictly controlled procedure “GCP/ICH” used in all pharmaceutical studies”.
In the 12-month, double-blind, placebo-controlled study, 180 overweight subjects randomized into three groups took CLA either as free fatty acid or as triglycerides, compared with placebo (olive oil). The research found that Tonalin® CLA supplementation reduced body fat by nine percent and increased lean muscle by two percent. The most remarkable effects on body composition were produced by trials performed with a mixture of the bioactive isomers (cis-9, trans- 11 and trans-10, cis-12). Measurements performed with dual-energy X-ray absorptiometry show significant changes over time: specifically, TONALIN® CLA generated a significant decrease in body fat, body weight and body mass index.
The research included analysis of lifestyle factors such as diet and training, and recorded aspects of quality-of-life, in order to evaluate the effect of CLA supplementation on the subjects’ day-to-day lives. In addition, the long-term safety of Tonalin® CLA was confirmed through rigorous recording of any side effects during the overall study, and analyses of blood parameters including blood lipids and diabetes markers. The research is due to be completed later this year.
Dr. Gaullier commented: “Reduction of body fat mass with maintenance or increase of lean mass is not only important for psychological well being but also because it decreases significantly the risk for developing diseases such as diabetes, cardiovascular disease, hypertension, gall bladder disease, osteoarthritis and some cancers.”
According to Kathleen Moran, Market Segment Manager, Dietary Supplements, for Cognis Nutrition and Health, “Numerous studies on Tonalin® CLA have consistently demonstrated its ability to reduce body fat in humans for improved overall body composition. Dr. Gaullier’s study is the first to examine CLA’s efficacy and effects long-term, and revealed the most significant body fat reduction and lean muscle mass increase to date. These results should further confirm the merits of Tonalin® CLA’s proprietary isomer profile to the industry and consumers alike.”
Tonalin® CLA - an exclusively licensed product of the Cognis Group - is the brand used in most clinical research confirming CLA’s benefits for human health, including seven published studies on CLA in the past 3 years. Cognis Nutrition & Health is launching the Tonalin® CLA brand in Europe at Vitafoods 2003 [Geneva, May 13-15].
*American Oil and Chemist Society
Media Contact: Val Holmes
Phone: +44 (0)20 8979 2333
E-mail: [email protected]
Mobile +44 (0)7775 615901 between 12-15 May 2003
Cognis Nutrition & Health, a business unit of Cognis Group, provides antioxidant, botanical and nature-based ingredients for dietary supplements; pharmaceuticals and healthcare; functional foods and medical nutrition, and animal nutrition. As a leader in food technology, Cognis manufactures emulsifiers, emulsifier-based compounds and numerous other speciality products for the food industry worldwide.
Cognis Nutrition & Health is exhibiting at stand 4811 at Vitafoods International 2003, Palexpo 5, Geneva, and is also this year’s Executive Exhibition Sponsor. Seminars on Tonalin® and the science of CLA are being held in the Vitafoods theatre at 1435 on May 13th, and 1105 on May 14th respectively.
Cognis is a worldwide supplier of innovative specialty chemicals and nutritional ingredients with almost 9,000 employees in close to 50 countries. The company has dedicated its activities to a high level of sustainability and delivers natural source raw materials and ingredients for food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Additionally, Cognis provides solutions for a number of other industries, such as coatings and inks, lubricants, textiles and plastics, as well as agro and mining.
Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and Schroder Ventures Life Sciences. In 2002, Cognis recorded sales of 3.1 billion euros and an operating profit before depreciation, amortization and exceptional items (EBITDA recurring) of 393 million euros.